Home/Pipeline/Treprostinil (Remodulin)

Treprostinil (Remodulin)

Pulmonary Arterial Hypertension

CommercialApproved

Key Facts

Indication

Pulmonary Arterial Hypertension

Phase

Commercial

Status

Approved

Company

United Therapeutics

About United Therapeutics

United Therapeutics Corporation is a biotechnology company dedicated to developing life-saving medicines for patients with rare diseases, particularly pulmonary arterial hypertension. Founded in 1996 by Dr. Martine Rothblatt, the company has successfully commercialized multiple breakthrough therapies and continues to advance innovative treatment approaches including gene therapy and xenotransplantation. With a strong financial position and diversified product portfolio, United Therapeutics is well-positioned to maintain its leadership in rare disease therapeutics.

View full company profile

Therapeutic Areas

Pulmonary Arterial Hypertension Rare Diseases Pulmonary Hypertension Gene Therapy Xenotransplantation

Other Pulmonary Arterial Hypertension Drugs

Drug	Company	Phase	Status
GSK3640254	GSK plc	Phase 2	Active
PAH Program	Insmed	Phase 2b	Completed
Treprostinil (Orenitram)	United Therapeutics	Commercial	Approved
Selexipag (Uptravi)	United Therapeutics	Commercial	Approved
Ralinepag	United Therapeutics	Phase 3	Active
Orenitram®	Supernus Pharmaceuticals	Approved/Commercial	Developed for United Therapeutics
Tadliq® (Tadalafil Oral Suspension)	CMP Pharma	Approved	Marketed